Award
National Institute of Allergy and Infectious Diseases 4R01AI180050-02
Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections
Recipient
West Virginia University, Morgantown, WV
Award Amount
$2,779,955.00
Ceiling
$2,779,955.00
Awarded
August 12, 2025
Identifier
4R01AI180050-02
This NIH-funded project focuses on developing and testing therapeutic antibodies against multidrug resistant Pseudomonas aeruginosa infections, aiming to improve treatment options for antibiotic-resistant infections.
Description
The goal of this proposal is to develop therapeutic antibodies for the treatment of multidrug resistant (MDR) P. aeruginosa infections, with an emphasis on sepsis. The project aims to characterize a therapeutic antibody cocktail targeting lipopolysaccharide (LPS) of P. aeruginosa, evaluate its efficacy against MDR clinical isolates, and assess its potential in preventing and treating MDR P. aeruginosa sepsis. The research will elucidate the mechanism of action of a novel class of antibodies capable of directly killing P. aeruginosa in vitro, and produce proof of concept data to support antibody therapy development.